Selected article for: "candidate vaccine and MERS cov vaccine candidate"

Author: Okba, Nisreen M. A.; Widjaja, Ivy; van Dieren, Brenda; Aebischer, Andrea; van Amerongen, Geert; de Waal, Leon; Stittelaar, Koert J.; Schipper, Debby; Martina, Byron; van den Brand, Judith M. A.; Beer, Martin; Bosch, Berend-Jan; Haagmans, Bart L.
Title: Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV
  • Cord-id: qbjrlog1
  • Document date: 2020_5_29
  • ID: qbjrlog1
    Snippet: Middle East respiratory syndrome coronavirus (MERS-CoV) is a WHO priority pathogen for which vaccines are urgently needed. Using an immune-focusing approach, we created self-assembling particles multivalently displaying critical regions of the MERS-CoV spike protein ─fusion peptide, heptad repeat 2, and receptor binding domain (RBD) ─ and tested their immunogenicity and protective capacity in rabbits. Using a “plug-and-display” SpyTag/SpyCatcher system, we coupled RBD to lumazine synthas
    Document: Middle East respiratory syndrome coronavirus (MERS-CoV) is a WHO priority pathogen for which vaccines are urgently needed. Using an immune-focusing approach, we created self-assembling particles multivalently displaying critical regions of the MERS-CoV spike protein ─fusion peptide, heptad repeat 2, and receptor binding domain (RBD) ─ and tested their immunogenicity and protective capacity in rabbits. Using a “plug-and-display” SpyTag/SpyCatcher system, we coupled RBD to lumazine synthase (LS) particles producing multimeric RBD-presenting particles (RBD-LS). RBD-LS vaccination induced antibody responses of high magnitude and quality (avidity, MERS-CoV neutralizing capacity, and mucosal immunity) with cross-clade neutralization. The antibody responses were associated with blocking viral replication and upper and lower respiratory tract protection against MERS-CoV infection in rabbits. This arrayed multivalent presentation of the viral RBD using the antigen-SpyTag/LS-SpyCatcher is a promising MERS-CoV vaccine candidate and this platform may be applied for the rapid development of vaccines against other emerging viruses such as SARS-CoV-2.

    Search related documents:
    Co phrase search for related documents
    • acute risk and live virus: 1, 2, 3, 4
    • acute sars cov respiratory syndrome coronavirus and live virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and live virus challenge: 1
    • acute sars cov respiratory syndrome coronavirus and live virus neutralization: 1, 2, 3, 4, 5, 6, 7